Open-label, Non-randomized, Single-center Study Investigating the Feasibility, Safety, Tolerability and Efficacy of Suizenji in Unresectable Pancreatic Ductal Adenocarcinoma Patients

This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a number of small ultrasound generators attached to a bowl-shaped ultrasound generator to emit ultrasound waves from outside to inside the body and focus them on a single point where cancerous cells in the pancreas are located. The targeted area is then heated, which kills the pancreatic cancer cells, and as a result, the patient's life may be prolonged. Experience with Suizenji for pancreatic cancer patients has shown that the "heating" is only a warm feeling in the abdomen during the treatment.

Start Date01 Dec 2025

Sponsor / Collaborator

Sonire Therapeutics Inc

NCT05700448

/ Not yet recruitingPhase 3

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

Start Date01 Dec 2025

Sponsor / Collaborator

CStone Pharmaceuticals Co. Ltd.

NCT07129772

/ Not yet recruitingPhase 2IIT

A Multicenter, Single Arm Phase II Study on Pembrolizumab and Chemotherapy as Perioperative Treatment Followed by Nasopharyngectomy and Maintenance Pembrolizumab for Locally Recurrent Nasopharyngeal Carcinoma (PINNACLE)

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse. Recent phase III randomized-controlled trials conducted in China demonstrated an improvement of progression-free survival with combinational therapy immune checkpoint inhibitors (ICI) (camrelizumab, toripalimab, and tislelizumab, respective) and chemotherapy gemcitabine (G) and cisplatin (P) compared with chemotherapy GP alone for recurrent or metastatic NPC. However, none of these studies have described in details the treatment outcomes of those subjects with locally recurrent NPC only, and whether any of these patients would undergo radical surgery to remove the residual locally recurrent NPC after ICI and chemotherapy. Continuation of the same ICI as maintenance therapy may only be the treatment option for these patients who were recruited into these phase III trials, unless if they withdrew from the study and opted for radical resection. While continuing the same ICI may still lead to persistent objective response and disease control, there is a possibility of tumor recurrence leading to unresectable disease and a worse survival outcome, or unexpected, rare but recognized immune-related emergent adverse events with ICI. Radical resection after maximal response to ICI and chemotherapy for patients with locally recurrent NPC only may provide a chance of cure of the disease and these patients may be obviated from continuous exposure to ICI therapy.
In view of the above, we are now proposing a phase II single-arm study on perioperative pembrolizumab and chemotherapy followed by radical surgery for locally recurrent NPC. As a collateral study, we will also perform single-cell DNA and RNA sequencing and proteomics study to observe the tumor and immune microenvironment which certainly helps us decipher the mechanisms of tumor response at genomic, transcriptomic and proteomic levels.

Start Date01 Nov 2025

Sponsor / Collaborator

The University of Hong Kong

[+3]

100 Clinical Results associated with Gemcitabine

100 Translational Medicine associated with Gemcitabine

100 Patents (Medical) associated with Gemcitabine

26,374

Literatures (Medical) associated with Gemcitabine

01 Mar 2026·BIOMATERIALS

Temperature-activated in situ hydrogel augments tumor treatment

Article

Author: Yang, Haojian ; Yu, Qianqian ; Yang, Ting ; Zhang, Cuiyun ; Wu, Qi ; Liu, Jihong ; Liang, Jiahui ; Wang, Qi ; Lin, Jiangtao ; Shi, Yiqi ; Xu, Shiyun ; Zhu, Wei-Hong ; Yao, Chenxing

In situ gels with tumor-targeted therapy often struggle with precise spatiotemporal drug release, compromising their efficacy in complex and heterogenous tumors. Here, we present a temperature-activated in situ hydrogel (PTT-Br@mPEG-PLGA and Gem@TCM-TK-PEG in chitosan and PF127 gel, denoted as PP + GC gel. Therein, the photothermal compound PTT-Br is fully named 6-bromo-1-ethyl-2-(2-(6-hydroxy-2,3-dihydro-1H-xanthen-4-yl)vinyl)quinolin-1-ium, while the reactive oxygen species (ROS)-responsive polymer TCM-TK-PEG is fully named tricyano methylene pyridine-thioketal-polyethylene glycol.) with the physiological temperature/photothermal/ROS-responsive drug store and release, thereby maximizing treatment outcomes. After intratumoral injection, PP + GC gel undergoes physiological temperature (37 °C)-responsive sol-gel phase transition, forming stable drug depot for enhanced tumor retention. Upon 635 nm laser irradiation, loaded photothermal agent converts light energy into heat (∼45 °C), triggering photothermal-responsive gel-sol phase transition for actively controlling encapsulated ROS-responsive therapeutic agents release, coupled with photothermal therapy. Subsequently, high levels of ROS in tumor cells disrupt the structure of ROS-responsive therapeutic agents, switching on the chemotherapeutic drug gemcitabine release and further stimulating immune response. Remarkably, laser irradiation of multiple short-duration induces a stronger immune response than that of single long-duration, thus achieving superior treatment outcomes. Benefiting from the smart control of photothermal therapy, chemotherapy, and immunotherapy, active PP + GC gel exhibits a tumor inhibition rate of approximately 82.25 % in melanoma-bearing mouse models, demonstrating significant antitumor efficacy while maintaining excellent biosafety.

01 Feb 2026·Biomaterials advances

Sustained and localized delivery of gemcitabine using chitosan-PVA-TPP polymeric implant enhances antitumor efficacy and delays surgical relapse in pancreatic cancer

Article

Author: Saha, Panchali ; Valvi, Snehal K ; De, Abhijit ; Bandyopadhyaya, Rajdip ; Kumari, Archana ; Thorat, Rahul ; Mal, Arijit ; Chilakapati, Murali Krishna ; Patel, Parikshit

Gemcitabine (GEM), one of the first lines of therapy in pancreatic cancer (PC) patients, has certain limitations, such as, low plasma half-life, limited bioavailability and treatment index. To address these issues, a localized and sustained delivery approach is undertaken, where we have developed a biodegradable polymeric film implant, by solvent casting method, using chitosan, polyvinyl alcohol (PVA), and sodium tripolyphosphate (TPP). Incorporating PVA and crosslinker TPP with chitosan enhances the mechanical strength of the chitosan film, evident from reduction of elastic modulus from 18.51 to 0.19 MPa. Under in vitro conditions, the film gradually releases GEM, exhibiting increased cell-killing capabilities in both 2D and 3D cell models and enhanced efficacy against GEM-resistant PC cells. Delivery through implant induces alteration of the lipid content of cells and significantly (p < 0.0001) enhances DNA double-strand break and antiproliferative properties. Furthermore, antitumor efficacy of GEM-loaded film (GEM-film) in pre-clinical settings significantly (p < 0.05) impairs tumor growth in advanced subcutaneous models and mitigates therapy resistance. GEM-film implants have proven ~7 times more effective in orthotopic models and have also delayed surgical relapse in PC mice models. Our study demonstrates that the delivery of GEM using the polymeric composite film is advantageous over that of free GEM in a pre-clinical context.

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Pi Ji Pills reshape the pancreatic cancer immune microenvironment and enhance the efficacy of gemcitabine through dual mechanisms of PI3K/AKT pathway blockade and NETs inhibition

Article

Author: Li, Yi ; Liu, Fudong ; Jiang, Xiaochen ; Pang, Bo ; Shen, Qian ; Lin, Hai ; Zhang, Chuanlong

ETHNOPHARMACOLOGICAL RELEVANCE:

Pancreatic cancer presents a significant challenge in clinical treatment. Pi Ji Pills (PJP) is a compound formula made up of seven traditional Chinese medicinal herbs. It has demonstrated positive clinical outcomes in the treatment of pancreatic cancer, and its potential pharmacological mechanisms warrant further investigation.

AIM OF THE STUDY:

This study aimed to identify the possible mechanisms by which PJP inhibits pancreatic cancer, followed by experimental verification and more profound exploration.

MATERIALS AND METHODS:

An in vivo pancreatic cancer xenograft model was established to observe the effect and safety of PJP on tumor growth. The SW1990 cells were cultured to investigate the intervention effects of PJP-containing serum on the malignant biological behavior of pancreatic cancer cells. Subsequently, network pharmacology analysis was employed to explore the potential mechanisms. Furthermore, both in vivo and in vitro experiments were conducted to validate the core pathways and targets. An in-depth exploration was performed, with a focus on the role of neutrophil extracellular traps (NETs) in the inhibition of pancreatic cancer by PJP.

RESULTS:

PJP inhibits tumor growth, and its combination with gemcitabine exhibits enhanced inhibitory effects, partially alleviating immune suppression. PJP-containing serum was found to inhibit the malignant biological behavior of SW1990 cells. naringenin, atractylenolide I, isoalantolactone, curcumenol, parthenolide, and arglabin are the main active components of PJP. PJP inhibits PI3K/AKT pathway, key to its anti-pancreatic cancer effects. Additionally, PJP's treatment inhibited SW1990 cell proliferation indenpence of reducing IL-8 and downregulating NETs-related protein expression in the co-culture system.

CONCLUSIONS:

PJP combats pancreatic cancer and enhances gemcitabine efficacy by remodeling the immunosuppressive tumor microenvironment. This anticancer effect may be attributed to a dual-target mechanism involving suppression of the PI3K/AKT pathway and regulation of NETs formation in the tumor microenvironment.

946

News (Medical) associated with Gemcitabine

14 Oct 2025

·www.prnewswire.com

iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with pancreatic cancer at ESMO

Cambritaxestat, the first autotaxin (ATX) inhibitor to be investigated in cancer patients, meets its primary endpoint in a study to assess safety and anti- tumour responses in patients with metastatic pancreatic cancer Combining cambritaxestat with gemcitabine/nab-paclitaxel (GnP) was tolerable and associated with anti-tumor responses Cambritaxestat administration combined with GnP demonstrated reduction in pharmacodynamic markers associated with fibrosis, immune regulation and tumor progression GENEVA and AMSTERDAM and CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- iOnctura, a clinical-stage precision oncology company focused on neglected and hard-to-treat cancers, today announces the Phase Ib study investigating oral autotaxin (ATX) inhibitor, cambritaxestat (IOA-289), has met the primary endpoint: demonstrating safety, tolerability and anti-tumor responses, in combination with standard-of-care chemotherapy, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). These data are being presented as a poster at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.1 Lead investigator, Davide Melisi, M.D., Ph.D, Associate Professor of Medical Oncology, and Director of the Digestive Molecular and Clinical Oncology Research Unit, University of Verona, and Investigational Cancer Therapeutics Clinical Unit at the University Hospital of Verona, Verona, Italy said, "These early findings with cambritaxestat are encouraging. Clinical activity alongside a manageable safety profile is particularly meaningful in a disease as aggressive and fibrotic as metastatic pancreatic cancer. These findings warrant continued scientific exploration in autotaxin inhibition." The Phase Ib dose escalation study, AION-02 (NCT05586516) evaluated cambritaxestat in combination with standard-of-care chemotherapy GnP in patients with previously untreated mPDAC. Sixteen patients received cambritaxestat orally, twice daily at doses of 100 mg (n=4), 200 mg (n=4), 400 mg (n=5) and 800 mg (n=3). GnP was administered by IV infusion, weekly for three weeks of a four-week cycle. The results show no dose-limiting toxicities, and no treatment-emergent adverse events (TEAE) leading to drug discontinuation or dose modification. Pharmacodynamic analysis showed a dose dependent reduction in the ATX-dependent plasma lipid LPA C18:2 over 24 hours supporting cambritaxestat's on-target effects. Patients in the higher-dose cohorts had consistent and durable reductions of the tumor marker CA19-9. These changes were associated with radiographic responses and survival. Dr. Michael Lahn, Chief Medical Officer at iOnctura said, "These data reinforce the therapeutic promise of targeting the autotaxin pathway to address the complex biology of pancreatic cancer, and potentially other tumors with high expression of autotaxin and its associated signaling. As we advance development, we remain focused on unlocking the potential of cambritaxestat to improve outcomes for patients facing some of the most challenging and hard-to-treat cancers." Cambritaxestat is the first autotaxin inhibitor to be investigated in cancer patients and is being developed as a first-in-class therapy across multiple cancer indications. This study was co-funded by the European Union and recruited patients in Italy and the United Kingdom. For more information contact: iOnctura Corporate Press Office: [email protected] About iOnctura iOnctura is a clinical-stage precision oncology company combating neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Lead asset, roginolisib, is an allosteric modulator of PI3Kδ with a unique chemical structure and binding mode. Allosteric modulation is a new archetype for precise inhibition of PI3Kδ, promising clinical activity without the detrimental tolerability seen with previous generations of inhibitors. Roginolisib is being investigated in multiple randomized Phase II studies in solid and hematological malignancies. iOnctura is headquartered in Amsterdam, The Netherlands with subsidiaries located in Geneva, Switzerland and Cambridge, MA, USA. iOnctura is backed by specialist institutional investors including Syncona, M Ventures, Inkef Capital, EIC Fund, VI Partners, Schroders Capital and XGEN Venture. About cambritaxestat Cambritaxestat is an orally administered autotaxin inhibitor being developed for the treatment of highly fibrotic cancers, including metastatic pancreatic cancer. By targeting the autotaxin pathway, cambritaxestat offers a novel three-pronged approach—directly inhibiting tumor growth, stimulating immune effector cells, and reducing fibrosis to enhance drug and immune cell access to the tumor. Cambritaxestat received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA), in March 2024. This study was co-funded by the European Union. 1 ESMO Abstract #2227P: A Quinzii et al. Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). Abstract available, 13 October 2025. Poster presented at the European Society of Medical Oncology (ESMO) congress, 19 October 2025. Logo: SOURCE iOnctura WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Clinical ResultOrphan DrugASCOPhase 2

14 Oct 2025

·firstwordpharma.com

Astellas' Vyloy misses OS goal in Phase II pancreatic cancer study

Astellas on Tuesday said its CLDN18.2-directed antibody Vyloy (zolbetuximab), when combined with chemotherapy, failed to show a survival benefit in treatment-naïve patients with metastatic pancreatic adenocarcinoma at the final analysis of a mid-stage study. The Phase II GLEAM trial assessed first-line Vyloy plus gemcitabine and nab-paclitaxel in 393 adults whose tumours expressed CLDN18.2 in at least 75% of cells. Astellas said the Vyloy combination fell short on the primary endpoint of overall survival (OS), although it maintained a favourable safety profile. The company indicated that it will conduct a comprehensive evaluation of the data and collaborate with investigators on disseminating additional findings, including secondary endpoints and subgroup analyses. Vyloy remains the only approved therapy for CLDN18.2-positive HER2-negative gastric or gastroesophageal junction cancer across multiple markets, including the US, the EU, Japan and China. Earlier this year, the Japanese drugmaker said Vyloy sales had “expanded beyond expectations,” generating JPY 12.2 billion ($85 million) in fiscal 2024. Meanwhile, in May, Astellas bagged ex-China rights to Evopoint Biosciences’ investigational antibody-drug conjugate (ADC) targeting CLDN18.2, dubbed XNW27011, which is currently being investigated in gastric, gastroesophageal and pancreatic cancers.

ADCClinical ResultPhase 2Drug ApprovalPhase 1

13 Oct 2025

·www.globenewswire.com

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European Society for Medical Oncology (ESMO 2025) Annual Congress and at Infectious Diseases Week (IDWeek) 2025 Annual Meeting. VCN-01 upcoming mini-oral presentation at ESMO 2025Expanded data from the VIRAGE trial investigating VCN-01 (zabilugene almadenorepvec) are to be presented at a mini oral session at the ESMO 2025 Congress: Presenting author: Dr. Rocío Garcia-Carbonero, Hospital 12 de Octubre, Madrid, SpainTitle: VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)Abstract #: 2216MODate and time: Monday, October 20, 2025, 09:28 a.m. CESTSession: Mini oral session 2, GI Tumors Upper digestiveLocation: Bonn Auditorium - Hall 7.1c, Messe Berlin, Berlin, Germany SYN-004 upcoming poster presentation at IDWeek 2025Previously disclosed blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). These data will be presented at ID Week 2025: Presenting Author: Erik R. Dubberke, MD, Professor of Medicine, Clinical Director, Transplant Infectious Diseases, Washington University School of Medicine in St. LouisTitle: Safety and tolerability of SYN-004 in allogeneic haematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)Abstract #: P-104Date and time: Monday, October 20, 2025 from 12:15 to 1:30 p.m US EDTLocation: Poster Hall B4-5, Georgia World Congress Center, Atlanta, Georgia About VCN-01 VCN-01 (zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus designed to selectively and aggressively replicate within tumor cells and degrade the tumor stroma that serves as a significant physical and immunosuppressive barrier to cancer treatment. This unique mode-of-action enables VCN-01 to exert multiple antitumor effects by (i) selectively infecting and lysing tumor cells; (ii) enhancing the access and perfusion of co-administered chemotherapy products; and (iii) increasing tumor immunogenicity and exposing the tumor to the patient’s immune system and co-administered immunotherapy products. Systemic administration enables VCN-01 to exert its actions on both the primary tumor and metastases. VCN-01 has been administered to 142 patients to date in clinical trials of different cancers, including pancreatic ductal adenocarcinoma (in combination with chemotherapy), head and neck squamous cell carcinoma (with an immune checkpoint inhibitor), ovarian cancer (with CAR-T cell therapy), colorectal cancer, and retinoblastoma (by intravitreal injection). More information on these clinical trials is available at Clinicaltrials.gov. About SYN-004 (ribaxamase) SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection following conditioning therapy. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients may lead to adverse outcomes including CDI, VRE colonization and potentially fatal bacteremia and aGVHD. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients who received SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com. For further information, please contact: Investor Relations:Kevin GardnerLifeSci Advisors, LLCkgardner@lifesciadvisors.com

Phase 2ImmunotherapyClinical Result

100 Deals associated with Gemcitabine

External Link

KEGG	Wiki	ATC	Drug Bank
D02368	Gemcitabine	L01BC05	DB00441

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 3	-	RenovoRx, Inc.	01 Jun 2023
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Australia	Panbela Therapeutics, Inc.	04 Aug 2022
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	United States	RenovoRx, Inc.	12 Mar 2018
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	Belgium	RenovoRx, Inc.	12 Mar 2018
Advanced Lung Squamous Cell Carcinoma	Phase 3	United States	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Belgium	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Canada	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	France	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Germany	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	Hungary	Sanofi	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2025	Not Applicable	Advanced biliary tract cancer First line	45	Cisplatin, Gemcitabine, Durvalumab	eahtznikrn(ivchebbhlx) = zrexwaqrra bgdtaiqgyu (dpmgxqmafp ) View more	Positive	30 May 2025
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	gemcitabine+Cisplatin (Chemotherapy (Cisplatin-Gemcitabine))	lnovudxrox(rxohcmbjzp) = vdfufeesrk toksziexpa (xtiesisvgg, octngondhv - ranbxpoxvs) View more	-	09 May 2025
NCT02807181 (SIRCCA, CTgov)	Phase 2/3	Unresectable Intrahepatic Cholangiocarcinoma	89	Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)+gemcitabine+Cisplatin (Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine))	lnovudxrox(rxohcmbjzp) = ostbdvisia toksziexpa (xtiesisvgg, vvzexagkag - qnoplqsvwa) View more	-	09 May 2025
NCT04602078 (AUREA \| SOGUG-AUREA, CTgov)	Phase 2	Urothelial Carcinoma of the Urinary Bladder \| Locally Advanced Urothelial Carcinoma \| Metastatic urothelial carcinoma	82	Cisplatin 70 mg/m2+Gemcitabine 1000 mg/m2+Atezolizumab 1200 mg/m2	xtjsqlfxpw = xmgfashegg cbvlpbbojs (mervxwggkt, sxmfpwrqrr - cixdwfuggz) View more	-	24 Apr 2025
NCT01972919 (CTgov)	Phase 2	Pancreatic carcinoma non-resectable	23	Radiation Therapy+Gemcitabine+Capecitabine	tamwpynlhq = hofgwgxvlc poscuosqgh (gcognpxgqm, leufzyzywt - oyhzngstkv) View more	-	10 Feb 2025
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	Phase 2/3	Metastatic Pancreatic Cancer Second line	317	Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA)	xldbetxngh(tglhnsbvnr): HR = 1.18 (95% CI, 0.88 - 1.56), P-Value = 0.14 View more	Negative	23 Jan 2025
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	Phase 2/3	Metastatic Pancreatic Cancer Second line	317	Gemcitabine/Abraxane (GA)		Negative	23 Jan 2025
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	19	Intra-arterial gemcitabine	lxnglhjzww(mgwylceuzx) = aablhimlsc kjpzisntqz (uofjpsouij )	Positive	23 Jan 2025
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	Phase 3	Locally Advanced Pancreatic Adenocarcinoma	19	Intravenous gemcitabine	lxnglhjzww(mgwylceuzx) = pnvjzvinxo kjpzisntqz (uofjpsouij )	Positive	23 Jan 2025
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	aeiabkhggr(vpcqdjcmvz) = foayzrlpbm dzmbrakfzx (lbfznaqyzx )	Positive	23 Jan 2025
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Glofitamab with Gemcitabine and Oxaliplatin	rgwllzdvzr(zoepikuaoz) = wehrhtjgst bzsdukpxxn (hebktiwptv, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Rituximab with Gemcitabine and Oxaliplatin	rgwllzdvzr(zoepikuaoz) = lthbkcyqxg bzsdukpxxn (hebktiwptv, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse large B-cell lymphoma recurrent	-	R-GemOx	xufnouikbh(sgvkvnyrif) = onibrcixvw rdujkfqlhr (khvkppylwy, 16‒29) View more	-	07 Dec 2024
NCT04989218 (ICC, CTgov)	Phase 1/2	Intrahepatic Cholangiocarcinoma	1	Tremelimumab+Gemcitabine+Cisplatin+Durvalumab	htvhaehhqn = pawgwvwldl zmjvpgfrdv (cnwrtoqcdl, revwjdejaz - rugqnqisks) View more	-	05 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis